Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06441331 · ClinicalTrials.gov registry record · Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

A Phase 1 study of Lymphoma and Solid Tumor, sponsored by ITM Solucin.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
2
Study locations

NCT06441331: Recruiting Phase 1 study of Lymphoma and Solid Tumor, sponsored by ITM Solucin.

NCT06441331 is a Phase 1 study of Lymphoma and Solid Tumor that is actively recruiting participants, run by ITM Solucin. The registered enrollment target is 20 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06441331, a Phase 1 study of Lymphoma and Solid Tumor, is actively recruiting participants, sponsored by ITM Solucin.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with somatostatin receptor (SSTR)-positive tumors.

Primary Outcome

Pediatric dosage based on: 1. absorbed dose by target organs (kidney and bone marrow). 2. rate of Dose limitting toxicities - based on adverse event reporting.

Interventions

  • OTHER Amino Acid Solution
  • DRUG Lutetium Lu 177-Edotreotide

Study Locations (2)

Pennsylvania

  • The Children's Hospital of Philadelphia (CHOP) - Philadelphia

Other

  • Hospital Universitario Vall d'Hebron - Oncología Médica - Barcelona

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-09-26
Est. Completion 2034-04
Phase Phase 1
ITM Solucin

3 total trials

What NCT06441331 shows while recruiting

NCT06441331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower).

The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Amino Acid Solution is the first listed.

NCT06441331 reports a single indexed study location in Pennsylvania, Other.

Frequently Asked Questions

What is clinical trial NCT06441331 about?

NCT06441331 is a clinical study titled "Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors". The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with soma...

What is the current status of trial NCT06441331?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-09-26. Estimated completion is 2034-04.

What conditions does trial NCT06441331 study?

This clinical trial studies the following conditions: Lymphoma, Solid Tumor, Rhabdomyosarcoma, GIST, CNS Tumors.

What interventions are being tested in trial NCT06441331?

The interventions under investigation include: Amino Acid Solution (OTHER), Lutetium Lu 177-Edotreotide (DRUG).

Who is sponsoring clinical trial NCT06441331?

This trial is sponsored by ITM Solucin, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06441331 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06441331's enrollment target sits among peer trials

20 246th of 299 higher than 49 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06441331, the US trial registry maintained by the National Library of Medicine. NCT06441331 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.